Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-DA-GDP followed by ASCT for transplant-eligible relapsed or refractory diffuse large B-cell lymphoma
ChiCTR2400092813Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polatuzumab vedotin, obinutuzumab, gemcitabine, cisplatin and dexamethasone in diffuse large B-cell lymphoma (DLBCL), sponsored by Beijing Hospital. Primary endpoint: Best overall response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
polatuzumab vedotinobinutuzumabgemcitabinecisplatindexamethasone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400092813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092813.